Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 06, 2024 08:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

NEW YORK, Feb. 06, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
January 30, 2024 08:00 ET | Source: MiNK Therapeutics

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
December 20, 2023 07:30 ET | Source: MiNK Therapeutics

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

MiNK Therapeutics combines its unique, proprietary library of T-cell antigens with ImmunoScape’s cutting-edge platform for rapid discovery of novel T-cell receptors Therapeutic development to focus on...
November 09, 2023 07:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Third Quarter 2023 Results

MiNK presents first-of-a-kind data with allogeneic iNKTs, agenT-797, showing durable clinical benefit in solid tumor cancers and persistence >6 months without toxic pre-conditioning.AgenT-797...
November 03, 2023 12:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6...
October 30, 2023 08:00 ET | Source: MiNK Therapeutics

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
September 27, 2023 09:05 ET | Source: MiNK Therapeutics

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
August 24, 2023 08:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Participate in September Investor Conferences

NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of...
August 10, 2023 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Reports Second Quarter 2023 Results

- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in...
July 28, 2023 08:30 ET | Source: MiNK Therapeutics

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company...